Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics.

The Massachusetts-based biotech company is under fire for refusing a request from the U.S. Food and Drug Administration to stop selling its Duchenne muscular dystrophy gene therapy, Elevidys. The AP reported that the FDA made the request after three patients who received gene therapies from Sarepta died, all from liver complications linked to treatment.

Sarepta said no.